Covered with hoops or self-pay: two doors compared in Missouri

There are two doors most Missourians face when standard treatment for depression or trauma-related symptoms has stopped helping. One is marked "covered, but slower." The other is marked "pay yourself, fewer steps." Neither door is labeled honestly enough. This comparison tries to fix that.

We start with the 443 people who took our summer poll in ten Midwest states. Asked to rate coverage as a reason to try, or pass on, ketamine or esketamine, 65 percent placed it at the top, as deciding or big. When coverage matters that much, the choice between these two doors is not a small detail. For most people it is the decision.

These poll figures are final; Pollfish has validated its panel.

First, a word for readers living with PTSD

Many people who find this page are carrying trauma, sometimes alongside depression, sometimes as the main thing. It is important to be precise here. The FDA approved Spravato, a nasal spray form of esketamine, for depression that resists treatment; PTSD is not among its approved uses. Ketamine used for PTSD is off-label, meaning it is outside any FDA approval for that condition.

That distinction matters for coverage as much as for medicine. Plans generally tie coverage to approved uses. If medication-resistant depression is part of your picture, the covered route may be open to you. If trauma symptoms are the primary concern, talk with a clinician about the full range of evidence-based options, which include trauma-focused therapies. Either way, your own clinician makes the call about fit.

You are not unusual for having tried and not found relief. Of those we polled, 72 percent knew firsthand, or through someone close, what it is like when standard medication leaves depression, anxiety, or PTSD in place.

Door one: covered, with hoops

What it usually is: esketamine given at a certified site, billed to your insurance, for treatment-resistant depression.

What the hoops look like:

• An evaluation confirming that your depression fits the criteria the plan uses.
• Records of your past antidepressant trials.
• A prior authorization request, typically submitted by the prescriber.
• A wait while the plan reviews it.

What you get for the trouble: a treatment given within its FDA approval, at a supervised site, with most of the cost handled by your plan after copays and deductibles. Approval matters to many people, and our respondents put it in the big or deciding tier 59 percent of the time.

What it asks of you in person: every session means a stay of two hours or more for observation, plus a driver to take you home. That does not change whether the plan pays or you do.

Door two: pay yourself, fewer steps

What it usually is: often a ketamine clinic offering IV infusions, or an at-home program with a remote prescriber. Some sites also offer esketamine on a self-pay basis.

What the simplicity looks like: no prior authorization, sometimes a quicker start, and a direct relationship with the clinic about scheduling.

What you give up: most or all of the cost lands on you. And depending on the option, you may be stepping outside the FDA-approved framework. At-home ketamine in particular is a grayer area than supervised, in-clinic esketamine, with less oversight in the room. Know which tradeoff you are choosing.

What people told us they would pick

We asked the choice straight out. A slim majority of respondents, 51 percent, chose the covered route even with more hoops. Nearly one in four preferred to pay themselves for a simpler path. The remaining 26 percent could not decide.

Being unsure is reasonable; it usually means you lack the two real prices. To gather them, start with how Brain Recovery Centers breaks down esketamine costs with and without insurance.

Side by side

• Cost to you: covered route, usually copays and deductibles; self-pay route, the full price, which varies widely by clinic and treatment type.
• Time to start: covered route, depends on authorization; self-pay route, often faster.
• Regulatory footing: covered esketamine sits within its FDA approval for treatment-resistant depression; self-pay options range from that same approval to off-label and at-home use.
• On-site time: esketamine requires supervised monitoring either way; other options vary by clinic.
• Who helps with paperwork: covered route, your prescriber and the site; self-pay route, little paperwork, but ask for written pricing.

How to choose between the doors

A few questions to ask yourself, and then to ask a clinician:

• Does depression that has not responded to medication describe my situation, or is something else driving what I feel?
• How much does FDA approval matter to me personally?
• What can my household realistically pay, and for how many sessions?
• How far away is the nearest in-network certified site, and who will drive me?

That travel question comes up often in Missouri, where the distance between towns can be long. Our respondents ranked a nearby provider second only to insurance, at 43 percent.

Who to ask first

Most respondents knew where they would begin: 56 percent with a primary doctor, 23 percent with a psychiatrist. For military families, bring every coverage card you carry, including TRICARE if you have it, because it can change which sites are open to you.

Whoever you see, tell them clearly that cost will shape your decision. That lets them point you toward the right door rather than the one that looks best on paper.

The honest limits

This comparison is not medical advice, and no route comes with a promised result. Esketamine's label names one condition, it is wrong for some people, and ketamine for PTSD is off-label. A clinician who knows your symptoms decides what fits.

If trauma or depression has turned your thoughts toward ending your life, act tonight. From Joplin to Hannibal, call or text 988 tonight, and veterans who call can press 1 once connected. The Suicide and Crisis Lifeline charges nothing, day or night.

Methodology

Pollfish survey 395586438 went out to consumer-panel members; Pollfish stopped fieldwork June 23, 2026, holding 443 completes; respondents were aged 18 to 64 and spread over Minnesota, Illinois, Nebraska, Ohio, Missouri, Wisconsin, Kansas, Iowa, Indiana and Oklahoma. We report the final whole-sample figures. The publisher commissioned the study at its own expense.